Background: EXCELS, a postmarketing observational cohort study, was a commitment to the US Food and Drug Administration to assess the long-term safety of omalizumab in an observational setting, focusing predominantly on malignancies. Objective: The aim of this study was to examine a potential association between omalizumab and cardiovascular (CV)/ cerebrovascular (CBV) events in EXCELS. Methods: Patients (> _12 years of age) with moderate to severe allergic asthma and who were being treated with omalizumab (n 5 5007) or not (n 5 2829) at baseline were followed up for < _5 years. Analyses included overall CV/CBV events, but focused on the subset of arterial thromboembolic events (ATEs), comprising CV death, myocardial infarction, ischemic stroke, transient ischemic attack, and unstable angina. A prespecified analysis of the end point of ATE was conducted to control for available potential confounders. A blinded independent expert panel adjudicated all events.
Omalizumab (Xolair; Genentech, Inc, South San Francisco, Calif) is a recombinant humanized monoclonal antibody directed against IgE. In randomized, placebo-controlled trials and in open-label studies in patients on maintenance therapy with inhaled corticosteroids (ICSs) and/or long-acting b-agonists, the addition of omalizumab has been shown to reduce asthma exacerbations, [1] [2] [3] [4] [5] [6] [7] [8] [9] decrease the use of ICSs and rescue medications, 1, 3, 5, 8, 10 and improve symptom control and quality of life. 1, 5, 8, 10 In EXCELS (Epidemiologic Study of Xolair [Omalizumab] : Evaluating Clinical Effectiveness and Long-term Safety in Patients With Moderate to Severe Asthma), a postmarketing observational cohort study, the primary objective was to assess the long-term (< _5 years) clinical safety profile of omalizumab, with a focus on malignancy. This observational study was designed to compare adverse events in patients with asthma whom health care providers had treated with omalizumab to those in patients with asthma who had not been treated with omalizumab. A numeric imbalance in malignancy rates in patients with allergic asthma in pivotal trials was the motivation for EXCELS. 3, 5 Accordingly, the primary outcome measures were primary malignancies, all malignancies excluding nonmelanoma skin cancer, and overall serious adverse events (SAEs). Details regarding the study design and methodology, including patients' baseline characteristics, have been published elsewhere. 11 In EXCELS, the incidence rates of primary malignancies (per 1000 person years [PYs]) were similar among patients treated with omalizumab and non-omalizumab-treated patients (12.3 vs 13.0); however, study limitations precluded definitively ruling out a malignancy risk with omalizumab. 12 In an interim effectiveness analysis, patients who started on treatment with omalizumab at enrollment showed clinically relevant improvements in asthma control that were maintained during 2 years of follow-up. 13 This analysis focused on cardiovascular (CV) and cerebrovascular (CBV) SAEs that occurred during EXCELS. EXCELS was not originally designed specifically to assess CV/CBV events. A numeric imbalance in various CV/CBV events was first observed in an interim analysis presented to the US Food and Drug Administration (FDA), prompting a disclosure of such findings by the FDA in 2009. 14 The interim analysis also resulted in the development of a prespecified statistical analysis plan supporting methodology for the ascertainment of CV-related events, including external adjudication, as detailed subsequently. An analysis of data pooled from multiple randomized, double-blind, placebo-controlled clinical trials of omalizumab was also planned after the results from the EXCELS interim analysis were evaluated. 15 
METHODS

Overview of EXCELS
EXCELS (ClinicalTrials.gov identifier: NCT00252135) was conducted as part of a postmarketing commitment to the FDA to assess the long-term safety and effectiveness of omalizumab in the clinical practice setting. Patients (> _12 years of age; N 5 7857) with moderate to severe asthma, willing to participate in a 5-year study, and with a history of either a positive response to allergy skin testing or in vitro serum-specific IgE reactivity to an aeroallergen were recruited from 445 US-based practice centers according to the use of omalizumab at or within 30 days of enrollment (2:1 ratio; omalizumab, n 5 5007; non-omalizumab, n 5 2829). Patients were excluded from EXCELS if they had: (1) a contraindication to omalizumab; (2) an asthma exacerbation that required initiation or increased doses of systemic corticosteroids, doubling of inhaled corticosteroid dosing, or an emergency department visit or hospitalization in the 2 weeks before screening; (3) acute flare of significant systemic disease or hospitalization for that disease in the 2 months prior to screening; and/or (4) use of an experimental drug within 30 days of screening, cystic fibrosis diagnosis, or participation in a blinded omalizumab study at screening or any time during the study. Patients in the non-omalizumab group could not have received any prior treatment with omalizumab. A small number of patients (n 5 21) who had previously been treated with omalizumab but were not taking the drug at study enrollment were not included in the analyses. Assessments included the collection of detailed information regarding demographic and clinical characteristics, physician-assessed asthma severity, spirometry, and patient-reported outcome measures. Study assessments were conducted every 6 months for the 5-year study duration.
This study was conducted in accordance with FDA regulations, the International Conference on Harmonisation E6 Guideline for Good Clinical Practice, and any other applicable country laws. Institutional review board approval was obtained at each study site, and informed consent was obtained from all research subjects.
Identification and adjudication of CV and CBV SAEs
In EXCELS, the definition of an SAE was any untoward medical occurrence that, after enrollment, resulted in a patient's death, was life-threatening, required prolonged inpatient hospitalization, was disabling, was a congenital anomaly/birth defect, or was medically significant or required medical or surgical intervention to prevent one of these outcomes, and was based on the definition of an SAE as outlined by the FDA. 16 During EXCELS, verbatim terms for all study-emergent SAEs were coded and analyzed using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Classes, High-Level Terms, and Preferred Terms. An independent panel of experts performed a blinded review of patient narratives and supporting documents for all SAEs that resulted in death and all potential CV/CBV SAEs identified using Standardized MedDRA Queries (Medical Dictionary for Regulatory Activities; http://www.meddra.org/ standardised-meddra-queries) (Fig 1) . This approach allowed for the identification of cases that were highly likely to have represented the condition of interest as well as the identification of all possible cases. The panel also classified the CV/CBV SAEs into standardized categories: myocardial infarction (MI), unstable angina, congestive heart failure, ischemic stroke, transient ischemic attack, hemorrhagic stroke, pulmonary embolism, venous thrombosis, pulmonary hypertension, arterial ischemic vascular disease, atrial fibrillation/flutter, and ventricular tachycardia/fibrillation.
An additional composite end point, arterial thromboembolic event (ATE), was defined using an approach adapted from the 2002 Antiplatelet Trialists' Collaboration. 17 The ATE category comprised CV/CBV events sharing a common pathophysiologic mechanism of arterial injury and/or inflammation and included CV death, MI, ischemic stroke, transient ischemic attack, and unstable angina.
Descriptive analyses
Data were analyzed in terms of PYs of observation, defined as the time from study day 0 to the date of death, date of event of interest, study completion, or the last completed clinic visit in those who discontinued from the study, whichever came first. Overall incidence rates per 1000 PYs of observation of adjudicated CV/CBV-related deaths and SAEs were calculated in each cohort and are reported with 95% CIs. Crude rate differences were calculated with 95% CIs. The same analyses were performed for each of the adjudicated event categories and for all event categories combined (CV or CBV SAEs).
The prespecified analysis of ATEs was applied to the cumulative adjudicated data for the evaluation of events with a common pathophysiology. As described for CV/CBV SAEs, overall incidence rates per 1000 PYs were calculated with 95% CIs for both cohorts. Crude rate differences and rate ratios were calculated with 95% CIs. Similarly, the rates of patients experiencing > _1 ATE event, expressed per 1000 PYs of observation time, were calculated by treatment cohort and reported with 95% CIs. A sensitivity analysis was conducted in which event rates per 1000 PYs were computed by treatment cohort for the set of ATEs that excluded deaths not associated with any of the following SAEs: MI, ischemic stroke, ventricular tachycardia, or ventricular fibrillation.
To adjust for potential confounders, we used a Cox proportional hazards regression model. The time to a patient's first ATE was defined as the number of months from study day 0 to the date of onset of symptoms of the first SAE experienced by the patient that met the ATE definition. Data from patients not experiencing an ATE were censored at the earliest of the following dates: death from a documented non-CV cause, loss to follow-up, discontinuation from the study, initiation of omalizumab treatment (non-omalizumab cohort only), >6 months after the omalizumab stop date (omalizumab cohort only), or study completion. A Cox proportional hazards model was fit for time to first study-emergent ATE to estimate the unadjusted hazard ratio between treatment cohorts and corresponding 95% CIs. Models were subsequently fit for time to first study-emergent ATE to estimate the hazard ratio between cohorts, with adjustments separately for each potential baseline CV/CBV risk factor. A final multivariate Cox proportional hazards model was developed to adjust fully for all available baseline CV/CBV risk factors, according to the prespecified analysis plan, with covariates for age (<65 vs > _65 years), sex, and asthma severity (severe vs moderate). Stepwise variable selection was then used to select a final model from potential baseline risk factors based on P < _.20 criteria for entry and P >.20 for removal. Model covariates can be found in Table E1 in this article's Online Repository at www.jacionline.org.
In addition, a post hoc exploratory analysis was conducted to compare ATE risk between the omalizumab and non-omalizumab cohorts, with adjustment for the estimated probability of receiving omalizumab. In each patient, a propensity score 18 was calculated using logistic regression to model the probability of receiving omalizumab as a function of potentially confounding baseline variables, including, but not limited to, age, race, ethnicity, sex, investigator-assessed asthma severity, IgE level, selected asthma and allergy history, and non-asthma-related medical history, as well as selected socioeconomic characteristics and variables specific to CV risk factors. Subsequent to trimming all nonoverlapping propensity score values between treatment cohorts, an additional 1% of observations were removed from the upper tail of the propensity score distribution in the omalizumab-treated group, in addition to removal of 1% of observations from the lower tail of the propensity score distribution in the non-omalizumab-treated group. Patients were then stratified into deciles according to each patient's propensity score. A standardized incidence rate per 1000 PYs was calculated for each treatment cohort, as well as a standardized rate difference and a rate ratio (using the omalizumab cohort as the standard).
Kaplan-Meier estimates were used for summarizing the distribution of time to first adjudicated study-emergent ATE SAE. All analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC).
RESULTS
PYs of follow-up
In the omalizumab cohort, the total cumulative PYs were 18,426 (mean 6 SD duration of follow-up, 3.7 6 1.8 years); in the non-omalizumab cohort, the total cumulative PYs were 9,963 (duration of follow-up, 3.5 6 1.9 years).
Patient disposition
Baseline demographic and clinical characteristics have been previously reported. 12 On average, the omalizumab cohort was slightly younger than the non-omalizumab cohort (44 vs 46 years, respectively). In both cohorts, ;65% were female and 80% were white. Clinical characteristics and CV risk factors are shown in Table I . Fifty-six percent of all patients remained in the study for 5 years and completed a clinic visit at month 60. The most frequently reported reasons for early discontinuation in the omalizumab and non-omalizumab groups, respectively, were patient decision (18% and 15%), loss to follow-up (16% and 15%), and physician decision (8% and 6%). In terms of person-time lost to follow-up, the proportions lost to follow-up were 26.4% in the omalizumab cohort and 29.6% in the non-omalizumab cohort.
The percentage of patients with severe asthma in the omalizumab cohort was more than twice that in the non-omalizumab cohort (49.6% vs 22.6%, respectively). Among patients with moderate asthma in the omalizumab cohort, 78.1% had used an asthma controller and 15.6% had used a quick-relief medication, in the 2 weeks before enrollment. In the non-omalizumab cohort, during the same time period, 69.8% of patients with moderate asthma had used an asthma controller and 11.9% had used a quick-relief medication. In both groups, the majority of patients with severe asthma were taking an ICS or long-acting ß-agonist to control their symptoms (see Table E2 in this article's Online Repository). By treatment cohort, a larger percentage of omalizumabversus non-omalizumab-treated patients reported chronic oral corticosteroid (OCS) use (7.5% vs 5.5%, respectively), which might be attributable to the larger percentage of omalizumabversus non-omalizumab-treated patients with moderate asthma taking OCSs (27.6% vs 24.4%, respectively; see Table E2 in this article's Online Repository). During the 5-year follow-up, more patients with severe asthma, regardless of treatment cohort, were taking an OCS than were those with moderate asthma (see Fig E1 in this article' s Online Repository). The overall pattern of OCS use was similar; the lowest use rate was measured at month 6 (range, 17% to 33%), and the highest use rate was measured at month 18 (range, 20% to 52%). Overall, the use of OCSs at baseline was higher among patients with severe versus moderate asthma (29% vs 26%, respectively).
Adjudicated study-emergent CV/CBV SAEs A higher incidence rate of CV/CBV SAEs was observed in the omalizumab-treated group (13.4 per 1000 PYs; 95% CI, 11.6-15.4) compared with the non-omalizumab-treated group (8.1 per 1000 PYs; 95% CI, 6.5-10.1) (Table II) . Higher rates were observed, respectively, for transient ischemic attack (0.7 vs 0.1 per 1000 PYs), MI (2.1 vs 0.8 per 1000 PYs), pulmonary hypertension (0.5 vs 0.0 per 1000 PYs), pulmonary embolism/ venous thrombosis (3.2 vs 1.5 per 1000 PYs), and unstable angina (2.2 vs 1.4 per 1000 PYs), while the rates observed for ischemic stroke and CV death were similar among both study cohorts.
Adjudicated study-emergent ATEs
The omalizumab cohort had higher rates (per 1000 PYs) of ATE SAEs, patients with ATE SAEs, and ATE SAEs (excluding non-ATE deaths) than did the non-omalizumab cohort (see Table  E3 in this article's Online Repository).
The unadjusted (crude) rates of ATEs per 1,000 PYs were 6.66 (101 patients with an ATE event per 15,160 PYs) in the omalizumab cohort and 4.64 (46 patients with an ATE event per 9,904 PYs) in the non-omalizumab cohort. The difference between the omalizumab and non-omalizumab cohorts in ATE rates per 1000 PYs was 2.02 (95% CI, 0.15-3.89), and the unadjusted rate ratio was 1.43 (95% CI, 1.00-2.08) (see Table E4 in this article's Online Repository). The adjusted Cox proportional hazards analysis indicated a hazard ratio of ATE events among those treated with omalizumab, compared with those who did not take omalizumab, of 1.32 (95% CI, 0.91-1.91; Table III ). After adjustment for the estimated probability of receiving omalizumab (propensity score), the difference between cohorts in ATE rates was 1.55 per 1000 PYs (95% CI, 20.87 to 3.97), and the rate ratio was 1.32 per 1000 PYs (95% CI, 0.83 to 2.12). The Kaplan-Meier estimates of time to first adjudicated study-emergent ATE are shown in Fig 2. 
DISCUSSION
Omalizumab has proven efficacy as adjunctive therapy in the management of moderate to severe allergic asthma. 1-9 EXCELS was conducted to collect longer-term safety data on omalizumab after approval. The results from the primary analysis of overall SAEs and malignancy have been previously published. 12 The current analysis of the EXCELS data revealed a higher crude incidence rate of CV/CBV SAEs in omalizumab-treated patients compared with non-omalizumab-treated patients. However, in the results from analyses of data pooled from 25 studies, 15 an association between omalizumab and CV/CBV SAEs or ATEs was not demonstrated. BMI, Body mass index. *Non-omalizumab cohort, female, n 5 2,827, white, n 5 2,826; omalizumab cohort, white, n = 5,006. Reported oral corticosteroid use in the past 12 months at the baseline visit.
In this nonrandomized study, confounding by indication for use of omalizumab was a possibility. 19, 20 While EXCELS was reasonably well-balanced for malignancy risk factors and showed similar rates of malignancy in the omalizumab and non-omalizumab cohorts, CV risk was greater at baseline in the omalizumab cohort, 21 possibly the result of the indication for omalizumab, such that the treated group included patients with more severe asthma. Higher rates of CV/CBV SAEs in the omalizumab cohort were noted when analyses were not adjusted for potential confounders. The findings were similar in the subset of CV/CBV SAEs meeting the definition of ATE. However, after taking confounding imbalances between the cohorts into account, using multivariate Cox regression analyses, stratification, and propensity score analyses, the crude associations were substantially reduced. We can expect that control of confounding was imperfect, and that the adjusted differences that we reported were affected by some further residual confounding, very likely in the same direction as the confounding that was controlled for.
Research indicates that asthma itself and the use of asthma medications may be independently associated with increased CV risk. [22] [23] [24] [25] [26] [27] [28] [29] An analysis of data from 6792 patients in the Multi-Ethnic Study of Atherosclerosis concluded that a subgroup of patients with asthma requiring controller medications, such as ICSs, had a higher rate of CV disease compared with the subgroup without asthma. 30 Additionally, as previously published, greater asthma severity predicted a higher risk for ATEs in the non-omalizumab cohort of EXCELS. 28 Multiple hypotheses exist for the observed association between asthma and CV outcomes. Potential mechanisms include medications used for treating asthma, [31] [32] [33] most notably OCSs, which are well known to increase the risk for CV risk factors such as diabetes, 34 and have been associated with an increased risk for adverse CV/CBV outcomes. [35] [36] [37] In patients with severe asthma, moderate to high exposure to chronic systemic corticosteroids appears to increase the risk for complications (eg, infections, CV events, metabolic events). 38 Additionally, a more direct link between asthma and CV disease has been suggested, by virtue of systemic inflammation associated with asthma as well as specific cytokine upregulation. [39] [40] [41] For example, the subgroup of patients with asthma requiring controller medications in the Multi-Ethnic Study of Atherosclerosis 30 had higher levels of the inflammatory markers C-reactive protein and fibrinogen than did the subgroups of patients without asthma and patients with asthma not requiring controller medications. Clinically, studies have confirmed that asthma severity measures, such as lung function impairment, are an independent risk factor for CV disease, and epidemiologic studies also have confirmed an association between asthma and comorbid diseases that increase CV risk, such as diabetes and chronic obstructive pulmonary disease. 34, 42 Elevated serum IgE levels have been described in some CV conditions and in patients with a positive history of CV disease. 43, 44 Moreover, IgE has been shown to be positively associated with CV risk. 45 None of these studies provides strong evidence that suggests that the anti-IgE properties of omalizumab contribute to an increased risk for CV events. In summary, no definitive biological relationship has been identified.
In our multivariate analysis, we were able to control for the imbalance in prevalence of severe asthma (49.6% in the omalizumab cohort vs 22.6% in the non-omalizumab cohort). Nonetheless, the dichotomous severity scale is unlikely to have captured all of the confounding by severity in data, leading to residual confounding. Additionally, there are likely to be unmeasured risk factors, including comorbid disease severity, further confounding the estimates.
Our findings also must be interpreted in the context of these and other limitations. For example, if the primary objective of EXCELS had been to examine CV/CBV outcomes rather than malignancies, more careful details about the CV risk factor *All non-omalizumab-or omalizumab-treated patients before any change in baseline treatment status. After initiation of omalizumab treatment (non-omalizumab cohort) or >6 months after last omalizumab dose (omalizumab cohort). àDefined as the time from day 0 to the earliest of the following events: study completion, death, first ATE SAE, start of omalizumab treatment (non-omalizumab cohort), >6 months after discontinuation of omalizumab (omalizumab cohort), or the last completed study visit date (discontinued patients). For patients who changed omalizumab treatment status, PYs at risk were calculated from omalizumab start date (non-omalizumab cohort) or >6 months after the end date (omalizumab cohort) to the earliest of the previously mentioned events. §Cox proportional hazard model including adjustments for baseline age, sex, steroid use, body mass index, smoking history, physician-assessed asthma severity (moderate vs severe), and the presence or absence of the following comorbidities: chronic obstructive pulmonary disease, congestive heart failure, depression, hypercholesterolemia, hypertension, type 2 diabetes.
profile, such as low-and high-density lipoprotein cholesterol levels or glycosylated hemoglobin levels to measure diabetes control, may have been collected. Second, ;90% of the patients in the omalizumab cohort were being treated with omalizumab before study enrollment. Consequently, only a minority of patients in the omalizumab cohort were new users. The experience of new users may well differ from that of prevalent users, who constituted the majority of exposed patients in our study. Additionally, 44.1% of study participants discontinued before the full 5 years of follow-up was completed, although only slightly more than one fourth of person-time was lost to follow-up. 12 Finally, the reported estimates are imprecise owing to the relatively low numbers of CV/CBV events adjudicated to the individual categories.
The results from EXCELS do not exclude a potential increased risk for CV/CBV SAEs in patients treated with omalizumab. After control for measured confounders, however, the magnitude of the estimated increase in risk was reduced considerably from the crude estimates. The assessment of CV/CBV risk should take into account the results from EXCELS and the pooled analysis of randomized controlled trials.
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Clinical implications: Current asthma-management guidelines should not be affected by the findings from this study of CV/ CBV SAEs in patients receiving omalizumab. However, health care professionals should be aware of a possible association of omalizumab with CV/CBV SAEs. Data are expressed as no. (%) of patients. *Physician-assessed asthma severity at baseline. Omalizumab, moderate asthma: n 5 2517; omalizumab, severe asthma: n 5 2480. àNon-omalizumab, moderate asthma: n 5 2183; non-omalizumab, severe asthma: n 5 635; omalizumab, severe asthma: n 5 2480. §Non-omalizumab cohort (moderate asthma, n 5 2183, severe asthma, n 5 635); omalizumab cohort (moderate asthma, n 5 2519, severe asthma, n 5 2480). *All non-omalizumab-or omalizumab-treated patients before any change in baseline treatment status. After initiation of omalizumab treatment (non-omalizumab cohort) or >6 months after last omalizumab dose (omalizumab cohort). àDefined as the time from day 0 to the earliest of the following events: study completion, death, start of omalizumab treatment (non-omalizumab cohort), >6 months after discontinuation of omalizumab (omalizumab cohort), or the last completed study visit date (discontinued patients). For patients who changed omalizumab treatment status, PYs at risk were calculated from omalizumab start date (non-omalizumab cohort) or >6 months after the end date (omalizumab cohort) to the earliest of the previously mentioned events. *Predictive probability of a patient receiving omalizumab as a function of baseline characteristics; patients were stratified into deciles according to their propensity score (higher scores/strata reflect a higher probability of receiving omalizumab). Defined as the time from day 0 to the earliest of the following events: study completion, death, start of omalizumab treatment (non-omalizumab cohort), 6 months after discontinuation of omalizumab (omalizumab cohort), first ATE SAE, or study visit date (discontinued patients). àAll non-omalizumab-or omalizumab-treated patients before any change in baseline treatment status.
